General
Preferred name
FASUDIL
Synonyms
FASUDIL HYDROCHLORIDE ()
HA-1077 (hydrochloride) ()
AT-877 (Hydrochloride) ()
Hexahydro-1-(5-isoquinolylsulfonyl)-1h-1,4-diazepine ()
AT877 ()
HA-1077, AT-877, ZK-258594 ()
AT-877 ()
Fasudil HCl ()
HA-1077 ()
Fasudil (HA-1077) HCl ()
HA-1077 hydrochloride ()
Fasudil HCl (HA-1077) ()
Fasudil (Hydrochloride) ()
fasudil ER ()
AT 877 ()
HA 1077 ()
NSC-759827 ()
ZK-258594 ()
HA-1077 dihydrochloride ()
Fasudil (ha-1077) hydrochloride ()
AT-877,HA-1077 HCl ()
Fasudil ()
P&D ID
PD001304
CAS
103745-39-7
105628-07-7
203911-27-7
Tags
available
drug
drug candidate
Approved by
PMDA
First approval
1995
Drug indication
Discovery agent
Drug Status
approved
investigational
Max Phase
2.0
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Fasudil is a potent inhibitor of the Rho-kinases ROCK1 and ROCK2.
(GtoPdb)
DESCRIPTION
Fasudil is a potent inhibitor of the Rho-kinases ROCK1 and ROCK2.
(PKIDB)
DESCRIPTION
Fasudil is a potent and selective Rho-kinase (ROCK) inhibitor and vasodilator. ROCK is an enzyme that participates in vasoconstriction and vascular remodeling. Fasudil is used for the treatment of cerebral vasospasm and has the potential to treat pulmonary hypertension as well as certain memory loss.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
HA-1077 is a potent and selective inhibitor of Rho kinase (ROCK). HA-1077 exhibited neuroprotective effects and enhanced cognition in mouse models of amyotrophic lateral sclerosis (ALS), suggesting its potential use for cognitive disorders such as ALS, Alzheimer's disease and spinal muscular atrophy. It also suppresses tumor cell motility and metastasis.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Protein kinase inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
Inhibitor of cyclic nucleotide dependent- and Rho-kinases
(Tocriscreen Plus)
DESCRIPTION
Inhibitor of cyclic nucleotide dependent- and Rho-kinases
(Tocriscreen Total)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
1
Compound Sets
33
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
Clinical kinase drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Other bioactive compounds
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
Tocriscreen Plus
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
70
Molecular Weight
291.1
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
1.22
TPSA
62.3
Fraction CSP3
0.36
Chiral centers
0.0
Largest ring
7.0
QED
0.9
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target Type
Enzymes
Target
Calcium Channel
ROCK
Autophagy
PKA
PKG
PKC
ROCK2
MLCK
PKIA, PRKACA, ROCK1, ROCK2
HIV
Autophagy,Calcium Channel,MLCK,PKA,PKC,PKG,Rho,ROCK
Pathway
Membrane Transporter/Ion Channel
TGF-beta/Smad
Stem Cell/Wnt
Cell Cycle/DNA Damage
Neuronal Signaling
Cell Cycle/Checkpoint
Apoptosis
Cytoskeletal Signaling
GPCR/G protein
Stem Cells
Protein Tyrosine Kinase/RTK
Epigenetics
Anti-infection
cytoskeleton
Targets
ROCK2,PRKACA,PRKACB,PRKACG,PRKCA,PRKCB,PRKCZ,PRKCH,PRKCG,PRKCD,PRKCI,PRKCE,PRKG1,PRKG2,MYLK
Primary Target
Rho-Kinases
MOA
PKA inhibitor
PKC inhibitor
ROCK inhibitor
Serine/threonin kinase inhibitor
Inhibitor
Calcium Sensitizers
Rho Kinase Inhibitors
rho associated kinase inhibitor
Member status
member
Indication
cerebral vasospasm
Solubility
In vitro:<br/>10 mM in DMSO
Source data